Search

Your search keyword '"Cassuto, E."' showing total 200 results
Start Over Author "Cassuto, E."
200 results on '"Cassuto, E."'

1. PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study

Author

Gaiffe, E., Crepin, T., Bamoulid, J., Courivaud, C., Büchler, M., Cassuto, E., Albano, L., Chemouny, J. M., Choukroun, G., Hazzan, M., Kessler, L., Legendre, C., Le Meur, Y., Ouali, N., Thierry, A., Anota, A., Nerich, V., Limat, S., Bonnetain, F., Vernerey, D., and Ducloux, D.

Published
2019
Full Text
View/download PDF

12. Risk of Perforated Colonic Diverticulitis in Patients With Chronic Kidney Disease Requiring Sodium Polystyrene Sulfonate

Author

Gaiffe, E., Crépin, T., Bamoulid, J., Courivaud, C., Büchler, M., Cassuto, E., Albano, L., Choukroun, G., Hazzan, M., Kessler, L., Legendre, C., Le Meur, Y., Ouali, N., Thierry, A., Anota, A., Nerich, V., Limat, S., Bonnetain, F., Vernerey, D., Ducloux, D., Nassereddine, Hussein, Pelletier, Anne-Laure, Chemouny, Jonathan Maurice, Rebibo, Lionel, Vrtovsnik, François, Msika, Simon, Couvelard, Anne, Sannier, Aurélie, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de néphrologie et immunologie clinique [CHRU Tours], Université de Tours (UT)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Service de Néphrologie, CHU Nice, Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Picardie Jules Verne (UPJV), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Strasbourg (UNISTRA), Domaines Océaniques (LDO), Centre National de la Recherche Scientifique (CNRS)-Institut d'écologie et environnement-Observatoire des Sciences de l'Univers-Université de Brest (UBO)-Institut national des sciences de l'Univers (INSU - CNRS), CHRU Brest - Service de Nephrologie (CHU - BREST - Nephrologie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Urgences néphrologiques et transplantation rénale [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Méthodologie et de Qualité de Vie en Cancérologie (UMQVC), Institut Régional Fédératif du Cancer (IRFC)-Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Pôle cancérologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM), Pathologies et épithéliums : prévention, innovation, traitements, évaluation (UR 4267) (PEPITE), Hôpital Bichat - Claude Bernard, CHU Pontchaillou [Rennes], Chirurgie digestive [CHU Amiens], CHU Amiens-Picardie, Service de Néphrologie [Bichat - Claude Bernard], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Louis Mourier - AP-HP [Colombes], Service de pathologie [CHU Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Pôle cancérologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut Régional Fédératif du Cancer (IRFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Pathologies et épithéliums : prévention, innovation, traitements, évaluation (EA 4267) (PEPITE), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Service de néphrologie et immunologie clinique, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours, Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Observatoire des Sciences de l'Univers-Institut d'écologie et environnement-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], Science et Technologie du Lait et de l'Oeuf (STLO), Institut National de la Recherche Agronomique (INRA)-AGROCAMPUS OUEST, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC)-Pôle cancérologie (CHU Besançon), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Institut Régional Fédératif du Cancer (IRFC), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (HOTE GREFFON), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC), Centre hospitalier universitaire régional de Besançon (CHRU Besançon), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Hopital Louis Mourier - AP-HP [Colombes], Institut Régional Fédératif du Cancer (IRFC)-Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC), Université de Tours-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC)-Pôle cancérologie (CHU Besançon), and Université de Franche-Comté (UFC)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

13. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study

Author

Tedesco-Silva, H., Pascual, J., Viklicky, O., Basic-Jukic, N., Cassuto, E., Kim, D. Y., Cruzado, J. M., Sommerer, C., Adel Bakr, M., Garcia, V. D., Uyen, H. -D., Russ, G., Soo Kim, M., Kuypers, D., Buchler, M., Citterio, Franco, Hernandez Gutierrez, M. P., Bernhardt, P., Chadban, S., Citterio F. (ORCID:0000-0003-0489-6337), Tedesco-Silva, H., Pascual, J., Viklicky, O., Basic-Jukic, N., Cassuto, E., Kim, D. Y., Cruzado, J. M., Sommerer, C., Adel Bakr, M., Garcia, V. D., Uyen, H. -D., Russ, G., Soo Kim, M., Kuypers, D., Buchler, M., Citterio, Franco, Hernandez Gutierrez, M. P., Bernhardt, P., Chadban, S., and Citterio F. (ORCID:0000-0003-0489-6337)

Abstract

BACKGROUND: The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) therapy using contemporary protocols in de novo kidney transplant recipients have not been compared in detail. METHODS: TRANSFORM was a randomized, international trial in which de novo kidney transplant patients were randomized to everolimus with reduced-exposure CNI (N = 1014) or mycophenolic acid (MPA) with standard-exposure CNI (N = 1012), both with induction and corticosteroids. RESULTS: Within the safety population (everolimus 1014, MPA 1012), adverse events with a suspected relation to study drug occurred in 62.9% versus 59.2% of patients given everolimus or MPA, respectively (P = 0.085). Hyperlipidemia, interstitial lung disease, peripheral edema, proteinuria, stomatitis/mouth ulceration, thrombocytopenia, and wound healing complications were more frequent with everolimus, whereas diarrhea, nausea, vomiting, leukopenia, tremor, and insomnia were more frequent in the MPA group. The incidence of viral infections (17.2% versus 29.2%; P < 0.001), cytomegalovirus (CMV) infections (8.1% versus 20.1%; P < 0.001), CMV syndrome (13.6% versus 23.0%, P = 0.044), and BK virus (BKV) infections (4.3% versus 8.0%, P < 0.001) were less frequent with everolimus. CMV infection was less common with everolimus versus MPA after adjusting for prophylaxis therapy in the D+/R- subgroup (P < 0.001). Study drug was discontinued more frequently due to rejection or impaired healing with everolimus, and more often due to BKV infection or BKV nephropathy with MPA. CONCLUSIONS: De novo everolimus with reduced-exposure CNI yielded a comparable incidence, though a distinctly different pattern, of adverse events versus current standard of care. Both regimens are safe and effective, yet their distinct profiles may enable tailoring for individual kidney transplant recipients.

Published
2019

15. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial

Author

de Fijter, J. W., Holdaas, H., Oyen, O., Sanders, J. -S., Sundar, S., Bemelman, F. J., Sommerer, C., Pascual, J., Avihingsanon, Y., Pongskul, C., Oppenheimer, F., Toselli, L., Russ, G., Wang, Z., Lopez, P., Kochuparampil, J., Cruzado, J. M., van der Giet, M., Gaite, L. E., Lopez, V. F., Maldonado, R., Massari, P., Novoa, P., Palti, G., Chadban, S., Kanellis, J., Masterson, R., Oberbauer, R., Saemann, M., Kuypers, D., Lohmus, A., Cassuto, E., Frimat, L., Lebranchu, Y., Le Meur, Y., Rostaing, L., Hauser, A., Muehlfeld, A., Nashan, B., Suwelack, B., Weithofer, P., Witzke, O., Zeier, M., Apostolou, T., Boletis, I., Gourmenos, D., Jasuja, S., Khullar, D., Ravishankar, M. S., Sharma, R. K., Garosi, G., Rigotti, P., Tisone, G., Todeschini, P., Acevedo, R., Rozentais, R., Juarez, F. J., Mier, G. M., Urrea, M., Machado, D., Nolasco, F., Sampaio, S., Dubanova, A., Lucan, M., Kolsanov, A. V., Medvedev, V. L., Moysyuk, Y. G., Nesterenko, V., Perlin, D. V., Ulyankina, I. V., Zagainov, E., Dalmau, A., Hernandez, D., Millan, S., Avhingsanon, Y., Turkmen, A., Tuncer, M., Yildiz, A., DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, Facolta' di MEDICINA e CHIRURGIA, Kuypers, Dirk, AII - Inflammatory diseases, Nephrology, AII - Amsterdam institute for Infection and Immunity, Groningen Kidney Center (GKC), and Groningen Institute for Organ Transplantation (GIOT)

Subjects
Graft Rejection, Male, HLA ANTIBODIES, immunosuppressant, kidney transplantation/nephrology, ELEVATE study, SIROLIMUS, immunosuppression/immune modulation, 030204 cardiovascular system & hematology, 030230 surgery, Pharmacology, Kidney Function Tests, Kidney Failure, 0302 clinical medicine, Postoperative Complications, cardiovascular disease, Risk Factors, Clinical endpoint, Immunology and Allergy, DONOR-SPECIFIC ANTIBODIES, Pharmacology (medical), Chronic, CARDIAC-HYPERTROPHY, Kidney transplantation, calcineurin inhibitor (CNI), clinical research/practice, clinical trial, kidney (allograft) function/dysfunction, mechanistic target of rapamycin: everolimus, Everolimus, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Survival, Humans, Immunosuppressive Agents, Kidney Failure, Chronic, Kidney Transplantation, Middle Aged, Prognosis, Tacrolimus, RENAL-TRANSPLANTATION, Kidney transplant, ELEVATE study, Certican, Life Sciences & Biomedicine, medicine.drug, medicine.medical_specialty, Certican, Urology, Renal function, Mycophenolic acid, 03 medical and health sciences, LEFT-VENTRICULAR MASS, PRESSURE-OVERLOAD, medicine, Kidney transplant, Transplantation, Science & Technology, business.industry, medicine.disease, Settore MED/18, Calcineurin, RECIPIENTS, MAMMALIAN TARGET, Sirolimus, CYCLOSPORINE, Surgery, business
Abstract

none 24 si In a 24-month, multicenter, open-label, randomized trial, 715 de novo kidney transplant recipients were randomized at 10-14 weeks to convert to everolimus (n = 359) or remain on standard calcineurin inhibitor (CNI) therapy (n = 356; 231 tacrolimus; 125 cyclosporine), all with mycophenolic acid and steroids. The primary endpoint, change in estimated glomerular filtration rate (eGFR) from randomization to month 12, was similar for everolimus versus CNI: mean (standard error) 0.3(1.5) mL/min/1.732 versus -1.5(1.5) mL/min/1.732 (p = 0.116). Biopsy-proven acute rejection (BPAR) at month 12 was more frequent under everolimus versus CNI overall (9.7% vs. 4.8%, p = 0.014) and versus tacrolimus-treated patients (2.6%, p < 0.001) but similar to cyclosporine-treated patients (8.8%, p = 0.755). Reporting on de novo donor-specific antibodies (DSA) was limited but suggested more frequent anti-HLA Class I DSA under everolimus. Change in left ventricular mass index was similar. Discontinuation due to adverse events was more frequent with everolimus (23.6%) versus CNI (8.4%). In conclusion, conversion to everolimus at 10-14 weeks posttransplant was associated with renal function similar to that with standard therapy overall. Rates of BPAR were low in all groups, but lower with tacrolimus than everolimus open de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group: [...; Guido Garosi; Paolo Rigotti; Giuseppe Tisone; Paola Todeschini; ...] de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group: [..; Guido Garosi; Paolo Rigotti; Giuseppe Tisone; Paola Todeschini; ..]

Published
2017

17. EPITOPE LOAD IS PREDECTIVE OF DE NOVO CLASS II DSA OCCURRENCE IN RENAL TRANSPLANT RECIPIENTS AFTER CONVERSION FROM CYCLOSPORINE TO EVEROLIMUS

Author

Snanoudj, R., Suberbielle, C., Kamar, N., Cassuto, E., Ohlmann, S., Parissiadis, A., Merville, P., Taupin, J. L., Thierry, A., Jollet, I., Grimbert, P., Anglicheau, D., Hazzan, M., Choukroun, Gabriel, de Ligny, B. Hurault, Janbon, B., Vuiblet, V., Sayegh, J., Le Meur, Y., Morelon, E., Buechler, M., Legendre, C. H., Hertig, A., Rondeau, E., DESSAIVRE, Louise, Service de néphrologie adultes [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Unité de recherche Génétique Microbienne (UGM), Institut National de la Recherche Agronomique (INRA), Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg), Service de Néphrologie-transplantation-dialyse [Bordeaux], CHU Bordeaux [Bordeaux], Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Poitiers, Université Paris Descartes - Paris 5 (UPD5), Labex_Transplantex (Labex_Transplantex), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Néphrologie et transplantation rénale Adultes [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre Hospitalier Universitaire [Grenoble] (CHU), Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), CHRU Brest - Service de Nephrologie (CHU - BREST - Nephrologie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de Transplantation, Néphrologie et Immunologie Clinique [Hôpital Edouard Herriot, HCL], Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Des Maladies Rénales Rares aux Maladies Fréquentes, Remodelage et Réparation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

21. Graft transmitted candidiasis in kidney transplantation: A multicenter study in France

Author

Albano, L, Kacso, I, Mainzer, MF, Desnos, M, Etienne, I, Hazzan, M, Westeel, Pf, Laouad, I, Hertig, A, Champion, L, Durrbach, A, Rostain, L, Mourad, G, Bretagne, Stéphane, Cassuto, E, Lortholary, O, Inconnu, Unité mixte de recherche biologie moléculaire et immunologie parasitaires et fongiques, Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire d'Alfort (ENVA)-Agence Française de Sécurité Sanitaire des Aliments (AFSSA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), ProdInra, Migration, and Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire - Alfort (ENVA)-Agence Française de Sécurité Sanitaire des Aliments (AFSSA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Published
2007

32. A PROSPECTIVE MULTICENTER OPEN-LABEL RANDOMIZED STUDY TO ASSESS EFFICACY AND SAFETY OF EVEROLIMUS WITH CICLOSPORINE-MICROEMULSION (CSA-ME) VERSUS EVEROLIMUS WITHOUT CALCINEURINE INHIBITOR WITH MYCOPHENOLATE SODIUM, IN MAINTENANCE ADULT KIDNEY TRANSPLANT PATIENTS: FOREVER STUDY

Author

CASSUTO, E., primary, Berthoux, F., additional, TOUPANCE, O., additional, MOULIN, B., additional, MOAL, M. C., additional, QUERE, S., additional, CHAOUCHE-TEYARA, K., additional, and Dantal, J., additional

Published
2010
Full Text
View/download PDF

37. LOWERING CYCLOSPORINE DOSE IS NOT ASSOCIATED WITH AN INCREASED RISK OF GASTRO-INTESTINAL ADVERSE EVENTS NOR THE NEED FOR DOSAGE DECREASE OF MYCOPHENOLATE MOFETIL.

Author

Kreis, H, primary, Miloradovich, T, additional, Mourad, G, additional, Cointault, O, additional, Berthoux, F, additional, Delahousse, M, additional, Cassuto, E, additional, Chalopin, J -M., additional, Glotz, D, additional, Lebranchu, Y, additional, Legendre, C, additional, Merville, P, additional, Touraine, J -L., additional, Vialtel, P, additional, Wolf, P, additional, Moulin, B, additional, and Purgus, R, additional

Published
2004
Full Text
View/download PDF

44. An open multicenter trial of conversion from sandimmun to neoral in stable kidney-transplant patients

Author

Hourmant, M., primary, Antoine, C., additional, Bayle, F., additional, Bedrossian, J., additional, Berthoux, F., additional, Cassuto, E., additional, Chalopin, J.M., additional, Charpentier, B., additional, Deteix, P., additional, Durand, D., additional, Hurault de Ligny, B., additional, Kessler, M., additional, Kreis, H., additional, Lang, P., additional, Lebranchu, Y., additional, Leroux-Robert, C., additional, Moulin, B., additional, Mourad, G., additional, Noël, C., additional, Olmer, M., additional, Potaux, L., additional, Pouteil-Noble, C., additional, Pruna, A., additional, Sraër, J.D., additional, Touchard, G., additional, Toupance, O., additional, Touraine, J.L., additional, Wolf, P., additional, Puget, S., additional, and Soulillou, J.P., additional

Published
1997
Full Text
View/download PDF

47. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.

Author

Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, Villar E, Pouteil-Noble C, Karaaslan H, Sichez H, Lasseur C, Delmas Y, Nogier MB, Fathallah M, Loundou A, Mayor V, Berland Y, Dussol, Bertrand, Morange, Sophie, and Burtey, Stéphane

Abstract

Background: Treatment of patients with membranous glomerulonephritis (MGN) is controversial because of the lack of clear benefit of the immunosuppressive regimens on patient or renal survival. The objective of this study is to evaluate the efficacy and safety of mycophenolate mofetil (MMF) for patients with MGN.Study Design: 1-year prospective, randomized, and controlled clinical trial.Setting& Participants: 36 patients with biopsy-proven idiopathic MGN and nephrotic syndrome.Intervention: 19 patients received MMF (2 g/d) for 12 months and 17 patients were in the control group. All patients had the same conservative treatment based on renin-angiotensin blockers, statins, low-salt and low-protein diet, and diuretics in case of edema.Outcomes& Measurements: End points were the mean proteinuria over creatinuria ratio in mg/g throughout the study and numbers of complete and partial remissions at 1 year (month 12). Data were analyzed on an intention-to-treat analysis.Results: Mean proteinuria over creatinuria ratio was stable in both groups throughout the study (P = 0.1). Mean proteinuria over creatinuria ratio was 4,690 +/- 2,212 mg/g in the MMF group and 6,548 +/- 4,601 mg/g in the control group (95% confidence interval of the difference, -619 to +4,247; P = 0.1). Remission was complete in 3 patients (1 in the MMF group, 2 in the control group; P = 0.5) and partial in 11 patients (6 in the MMF group, 5 in the control group; P = 0.9). The probability of complete or partial remission did not differ between the 2 groups after 12 months (relative risk, 0.92; 95% confidence interval, 0.48 to 1.75; P = 0.7). Kidney function was stable in the 2 groups according to estimated glomerular filtration rate and serum creatinine level.Limitations: The small number of patients and short follow-up prevent generalizations.Conclusions: A 12-month regimen of MMF did not decrease mean proteinuria over creatinuria ratio or increase partial and complete remissions. Serious adverse effects were observed in 4 patients (20%) receiving MMF. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

49. Formation of covalently closed heteroduplex DNA by the combined action of gyrase and RecA protein

Author

Cassuto E

Subjects
Biology, medicine.disease_cause, DNA gyrase, General Biochemistry, Genetics and Molecular Biology, Substrate Specificity, chemistry.chemical_compound, Plasmid, Type I topoisomerase, Escherichia coli, medicine, Molecular Biology, Base Sequence, General Immunology and Microbiology, General Neuroscience, Circular bacterial chromosome, Nucleic Acid Heteroduplexes, Kinetics, Rec A Recombinases, DNA Topoisomerases, Type II, Biochemistry, chemistry, biology.protein, DNA supercoil, DNA, Research Article, Plasmids, Heteroduplex
Abstract

The concerted action of DNA gyrase and RecA protein of Escherichia coli on intact and gapped homologous or partially homologous plasmid DNA molecules leads to the formation of covalently closed DNA containing one strand of each parental molecule. Large regions of non-homology can be incorporated into the closed circular duplex. Both proteins are essential for the reaction to take place, and type I topoisomerase cannot substitute for DNA gyrase.

Published
1984

50. Biosynthèse des caroténoïdes acycliques chez un mutant de Rhodotorula mucilaginosa

Author

Malengé Jp, Villoutreix J, and Nusbaum-Cassuto E

Subjects
Genetics, chemistry.chemical_classification, Mutation, organic chemicals, Mutant, Biophysics, food and beverages, Biology, medicine.disease_cause, Biochemistry, Molecular biology, Rhodotorula mucilaginosa, Pigment, chemistry.chemical_compound, Phytoene, chemistry, visual_art, medicine, visual_art.visual_art_medium, Nitrogen source, Molecular Biology, Ultraviolet radiation, Carotenoid
Abstract

In a mutant of Rhodotorula mucilaginosa 2-hydroxybiphenyl produces an inhibition of pigmentation accompanied by the accumulation of phytoene. After elimination of the inhibitor and in the absence of exogenous carbon or nitrogen source, the cells colour rapidly. We have followed the evolution of each carotenoid as a function of time; the results obtained allow one to exclude the hypothesis of the independent formation of carotenoids and provide conclusive proof for the role of phytoene as a precursor of acyclic carotenoids.

Published
1967

Catalog

Books, media, physical & digital resources
See catalog results